Abstract
Liver cancer is the common malignant tumor in China and current treatment is based on surgery. However, liver function of many liver cancer patients is impaired before surgery, so there’s a high possibility of occurrence of liver failure after the tumor resection. Therefore, it’s necessary to accurately evaluate liver function before surgery. Currently, clinical methods are mostly limited to assess the function of overall liver. But the application of hepatocyte-specific contrast agent—gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) makes it possible to assess the function of local liver segment accurately. This paper reviewed the progress of using Gd-EOB-DTPA dynamic contrast enhanced magnetic resonance imaging (MRI) to assess liver function preoperatively, such as parameters selection for liver function assessment, clinical factors affecting Gd-EOB-DTPA enhanced MRI and so on.
Highlights
Liver cancer is the common malignant tumor in China, and ranks third in all the tumor incidence [1] [2]
This paper reviewed the progress of using Gd-EOB-DTPA dynamic contrast enhanced magnetic resonance imaging (MRI) to assess liver function preoperatively, such as parameters selection for liver function assessment, clinical factors affecting Gd-EOB-DTPA enhanced MRI and so on
That is to say, when there is an excretion disorder in one of the two ways, it can be compensated by another way; 2) To achieve the same degree of development, Gd-EOB-DTPA requires only one quarter of the amount of Gd-DTPA [21]; 3) Compared with Gd-DTPA, Gd-EOB-DTP can reach developmental requirements 20 min after injection instead of 40 min, significantly reducing inspection time; (4) Gd-EOB-DTPA is safer because it causes less adverse reactions [22] (Table 2)
Summary
Liver cancer is the common malignant tumor in China, and ranks third in all the tumor incidence [1] [2]. The latter is an important reason for the liver failure [4]. Clinical commonly used methods are limited in assessing overall liver function, not accurately assessing local segment liver function [5] [6]. Gd-EOB-DTPA is a new kind of multifunctional magnetic resonance contrast agent produced by Bayer Schering Pharma AG in 1992, and it has undergone I, II, and III clinical trials since [7] It was officially listed in China in July 2011 [8]. This review will focus on the progress of Gd-EOB-DTPA used in liver function assessment
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
